Quintiles launches new solution to meet needs of Asia-Pac emerging biopharma cos

Emerging companies give region strong base to transform global healthcare

Quintiles  has launched a new solution set tailored to meet the needs of emerging companies in the world’s most diverse and dynamic healthcare market.

The Quintiles Asia-Pacific Emerging Biopharma solution includes dedicated local project leadership based in Asia-Pac with knowledge of local markets, customs and language, custom-tailored operational models to meet individual customer priorities and use Quintiles’ world-class processes and platforms and accelerated patient recruitment through Quintiles’ global network of 25 Prime and >1,200 Partner sites – with seven of those Prime Sites located in Asia-Pacific.

This further adds to Quintiles’ solutions for emerging companies, which includes Novella Clinical, a specialty CRO focused on the needs of small to mid-sized oncology companies and medical device and diagnostic companies.

“Asia-Pacific is poised to become the world’s next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines,” said Ross Horsburgh, Senior Vice President, Quintiles Head of Clinical Development, Asia-Pacific.  “These companies face formidable challenges as they look to expand into markets or therapeutic areas in which they may have limited or no experience. From start-ups to larger emerging players, our Asia-Pac solution is designed to improve their probability of success, whether their growth aspirations are regional or global.”

Asia-Pacific Emerging Biopharma solutionQuintilesRoss Horsburgh